Skip to main content
. 2012 Oct 31;24(4):1067–1073. doi: 10.1093/annonc/mds541

Figure 2.

Figure 2.

Percentages of patients with a complete response (no emesis and no rescue therapy). *P < 0.005 versus placebo group (calculated using the Mantel–Haenszel test after stratification for treatment, sex, presence or absence of at least moderately emetogenic antitumour agent used in combination with cisplatin, and presence or absence of previous treatment with cisplatin). Fosaprepitant group: n = 173; placebo group: n = 167 (overall phase and acute phases), n = 166 (delayed phase).